<DOC>
	<DOCNO>NCT02923180</DOCNO>
	<brief_summary>This study evaluate safety , anti-tumor effect , immunogenicity Enoblituzumab give radical prostatectomy . All patient receive Enoblituzumab 6 weekly dos begin 50 day prior radical prostatectomy .</brief_summary>
	<brief_title>Neoadjuvant Enoblituzumab ( MGA271 ) Men With Localized Intermediate High-Risk Prostate Cancer</brief_title>
	<detailed_description>This single-center , single arm , open-label pilot study evaluate safety , anti-tumor effect , immunogenicity neoadjuvant MGA271 give prior radical prostatectomy men intermediate high-risk localized prostate cancer . Patients recruit outpatient Urology clinic . Eligible patient receive MGA271 dose 15mg/kg IV give weekly 6 dos begin 50 day prior radical prostatectomy . 14 day last dose MGA271 , prostate gland harvest time radical prostatectomy , prostate tissue examine secondary endpoint . Follow-up evaluation adverse event occur 30 day 90 day surgery . Patients follow urologist accord standard institutional practice , require PSA evaluation every 3 ( ±1 ) month year 1 every 6 ( ±2 ) month year 2-3 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate ( clinical stage T1cT3b , N0 , M0 ) without involvement lymph node , bone , visceral organ Initial prostate biopsy available central pathologic review , confirm show least 2 positive core Gleason sum ≥7 Radical prostatectomy schedule Johns Hopkins Hospital Age ≥18 year ECOG performance status 01 , Karnofsky score ≥ 70 % ( see Appendix A ) Adequate bone marrow , hepatic , renal function : WBC &gt; 3,000 cells/mm3 ANC &gt; 1,500 cells/mm3 Hemoglobin &gt; 9.0 g/dL Platelet count &gt; 100,000 cells/mm3 Serum creatinine &lt; 1.5 × upper limit normal ( ULN ) Serum bilirubin &lt; 1.5 × ULN ALT &lt; 3 × ULN AST &lt; 3 × ULN Alkaline phosphatase &lt; 3 × ULN The etiology abnormal bilirubin transaminase level evaluate prior study entry . Willingness provide write informed consent HIPAA authorization release personal health information , ability comply study requirement ( note : HIPAA authorization include informed consent ) Willingness use barrier contraception time first dose MGA271 time prostatectomy . Presence known lymph node involvement distant metastases Other histologic type prostate cancer ductal , sarcomatous , lymphoma , small cell , neuroendocrine tumor Prior radiation therapy , hormonal therapy , biologic therapy , chemotherapy prostate cancer Prior immunotherapy/vaccine therapy prostate cancer Prior use experimental agent prostate cancer Concomitant treatment hormonal therapy 5αreductase inhibitor Current use systemic corticosteroid use systemic corticosteroid within 4 week enrollment ( inhaled corticosteroid asthma COPD permit nonsystemic steroid topical corticosteroid ) History presence autoimmune disease require systemic immunosuppression ( include limit : inflammatory bowel disease , systemic lupus erythematosus , vasculitis , rheumatoid arthritis , scleroderma , multiple sclerosis , hemolytic anemia , Sjögren syndrome , sarcoidosis ) History malignancy within last 3 year , exception nonmelanoma skin cancer superficial bladder cancer Uncontrolled major active infectious , cardiovascular , pulmonary , hematologic , psychiatric illness would make patient poor study candidate Known prior current history HIV and/or hepatitis B/C</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>